Misoprostol — Membership Pricing

Other medications in Digestive Health

• Natalizumab
• Obeticholic Acid
• Ondansetron
• Ozanimod
• Pancrelipase
• Plecanatide
• Polyethylene Glycol
• Prochlorperazine

About Misoprostol

Misoprostol is a versatile medication with several important uses, from protecting your stomach to assisting in obstetric care. Understanding your prescription is key, and finding affordable access is where TheDrugClub comes in. Our membership program helps you save significantly on medications like misoprostol, ensuring you can manage your health without breaking the bank.

What Misoprostol Treats

Misoprostol is a synthetic prostaglandin E1 analog, meaning it mimics natural substances in the body. Its primary and most well-known use is for preventing stomach ulcers, particularly in individuals taking nonsteroidal anti-inflammatory drugs (NSAIDs) for conditions like arthritis. NSAIDs can irritate the stomach lining, and misoprostol helps protect it by reducing stomach acid secretion and increasing protective mucus and bicarbonate.

Beyond ulcer prevention, misoprostol has critical applications in obstetrics and gynecology. It is widely used off-label for inducing labor, ripening the cervix, and managing incomplete miscarriage or abortion. It can also be prescribed to prevent or treat postpartum hemorrhage, a serious complication after childbirth, by causing the uterus to contract. Due to its potent effects on the uterus

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Misoprostol is approved for (FDA label)

Misoprostol is indicated for reducing the risk of NSAID (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. Misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking NSAIDs. Misoprostol should be taken for the duration of NSAID therapy. Misoprostol has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. It had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with NSAID use.

Source: Read the full FDA label on DailyMed. Label effective date: August 25, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Misoprostol (FDA label)

WARNINGS MISOPROSTOL ADMINISTRATION TO WOMEN WHO ARE PREGNANT CAN CAUSE BIRTH DEFECTS, ABORTION, PREMATURE BIRTH OR UTERINE RUPTURE. UTERINE RUPTURE HAS BEEN REPORTED WHEN MISOPROSTOL WAS ADMINISTERED IN PREGNANT WOMEN TO INDUCE LABOR OR TO INDUCE ABORTION. THE RISK OF UTERINE RUPTURE INCREASES WITH ADVANCING GESTATIONAL AGES AND WITH PRIOR UTERINE SURGERY, INCLUDING CESAREAN DELIVERY (see also PRECAUTIONS and LABOR AND DELIVERY ). MISOPROSTOL SHOULD NOT BE TAKEN BY PREGNANT WOMEN TO REDUCE THE RISK OF ULCERS INDUCED BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) (see CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). PATIENTS MUST BE ADVISED OF THE ABORTIFACIENT PROPERTY AND WARNED NOT TO GIVE THE DRUG TO OTHERS. Misoprostol should not be used for reducing the risk of NSAID-induced ulcers in women of childbearing potential unless the patient is at high risk of complications from gastric ulcers associated with use of the NSAID, or is at high risk of developing gastric ulceration. In such patients, misoprostol may be prescribed if the patient • has had a negative serum pregnancy test within 2 weeks prior to beginning therapy. • is capable of complying with effective contraceptive measures. • has received both oral and written warnings of the hazards of misoprostol, the risk of possible contraception failure, and the danger to other women of childbearing potential should the drug be taken by mistake. • will begin misoprostol only on the second or third day of the next normal menstrual period.

Source: FDA prescribing information (DailyMed). Set ID: c4fe14fb-0a43-4c31-9cd6-29eb0d156705. SPL document ID: a2441a04-9c20-452a-91e2-025ad1657568. Label effective date: August 25, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Misoprostol (FDA label)

The following have been reported as adverse events in subjects receiving misoprostol: Gastrointestinal In subjects receiving misoprostol 400 or 800 mcg daily in clinical trials, the most frequent gastrointestinal adverse events were diarrhea and abdominal pain. The incidence of diarrhea at 800 mcg in controlled trials in patients on NSAIDs ranged from 14–40% and in all studies (over 5,000 patients) averaged 13%. Abdominal pain occurred in 13–20% of patients in NSAID trials and about 7% in all studies, but there was no consistent difference from placebo. Diarrhea was dose-related and usually developed early in the course of therapy (after 13 days), usually was self-limiting (often resolving after 8 days), but sometimes required discontinuation of misoprostol (2% of the patients).

Source: FDA prescribing information (DailyMed). Set ID: c4fe14fb-0a43-4c31-9cd6-29eb0d156705. SPL document ID: a2441a04-9c20-452a-91e2-025ad1657568. Label effective date: August 25, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Misoprostol (FDA label)

Drug interactions See Clinical Pharmacology . Misoprostol has not been shown to interfere with the beneficial effects of aspirin on signs and symptoms of rheumatoid arthritis. Misoprostol does not exert clinically significant effects on the absorption, blood levels, and antiplatelet effects of therapeutic doses of aspirin. Misoprostol has no clinically significant effect on the kinetics of diclofenac or ibuprofen. Prostaglandins such as misoprostol may augment the activity of oxytocic agents, especially when given less than 4 hours prior to initiating oxytocin treatment. Concomitant use is not recommended.

Source: FDA prescribing information (DailyMed). Set ID: c4fe14fb-0a43-4c31-9cd6-29eb0d156705. SPL document ID: a2441a04-9c20-452a-91e2-025ad1657568. Label effective date: August 25, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.